Case number 2017-1094
Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 15, 2018 | 110 | ORDER filed. Teva's motion [105] is granted only to the extent that 2017-1444 is withdrawn. Amneal's motion [103] is granted only to the extent that 2017-1094 is withdrawn. Each party shall bear its own costs in 2017-1444 and 2017-1094. The revised official caption for 2017-1240, -1455, -1887 is reflected in the order. The parties are directed to file new briefs in 2017-1240, -1455, -1887, limited to the matters now on appeal. Endo's opening brief is due no later than April 6, 2018. Appellees' response briefs are due no later than April 20, 2018. Endo’s reply brief and the joint appendix are due no later than April 27, 2018. ISSUED AS A MANDATE (as to 2017-1444 and 2017-1094 only): March 15, 2018. Service: 03/15/2018 by clerk. [505691] [17-1240, 17-1444, 17-1094] [LMS] [Entered: 03/15/2018 04:10 PM] (4) |
| Feb 26, 2018 | 108 | RESPONSE of Cross-Appellant Endo Pharmaceuticals Inc. to the motion to terminate appeal [103] filed by Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC in 17-1094 , motion to terminate cross/consolidated appeal [105] filed by Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. in 17-1094. Service: 02/26/2018 by email. [501164] [Martin Black] [Entered: 02/26/2018 04:42 PM] (30) |
| Feb 26, 2018 | 109 | Sealed or confidential document received [Confidential Plaintiff-Corss-Appellant Endo Pharmaceuticals Inc.'s Response to the Defendants-Appellants' Motion to Dismiss] (corresponding to Doc No. [108]) for Cross-Appellant Endo Pharmaceuticals Inc.. Service: 02/26/2018 by email. [501166] [Martin Black] [Entered: 02/26/2018 04:43 PM] (0) |
| Feb 16, 2018 | 107 | Notice from Cross-Appellant Endo Pharmaceuticals Inc. Intent to Respond to Motions to Dismiss. Service: 02/16/2018 by email. [498938] [Martin Black] [Entered: 02/16/2018 12:33 PM] (3) |
| Feb 15, 2018 | 103 | MOTION of Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC to terminate appeal through dismissal as moot. [Consent: partial consent]. Service: 02/15/2018 by email. [498221] [Brenda Joly] [Entered: 02/15/2018 04:35 PM] (11) |
| Feb 15, 2018 | 104 | Sealed or confidential document received [MOTION of Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC to terminate appeal through dimissal as moot] (corresponding to Doc No. [103]) for Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 02/15/2018 by email. [498227] [Brenda Joly] [Entered: 02/15/2018 04:39 PM] (0) |
| Feb 15, 2018 | 105 | MOTION of Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. to terminate cross/consolidated appeal. Any response is due within 10 days of service [Consent: partial consent]. Service: 02/15/2017 by email. [498338] [Huiya Wu] [Entered: 02/15/2018 07:35 PM] (6) |
| Feb 15, 2018 | 106 | Sealed or confidential document received [Motion of Teva Pharmaceuticals USA, Inc. and Barr Laboratories, Inc., to Dismiss Appeal No. 2017-1444 as Moot] (corresponding to Doc No. [105]) for Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. Service: 02/15/2018 by US mail, email. [498340]--[Edited 02/16/2018 by ML to add party filers]. [Huiya Wu] [Entered: 02/15/2018 07:44 PM] (0) |
| Feb 14, 2018 | 102 | Notice from Cross-Appellant Endo Pharmaceuticals Inc. regarding conflicts with oral argument (April 9, 2018 and please do not schedule for the same week as appeal Nos. 17-2434, -2435). Service: 02/14/2018 by email. [497745] [Martin Black] [Entered: 02/14/2018 03:35 PM] (3) |
| Jan 29, 2018 | 101 | Notice from Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument ([update from 12/6/2017 ltr]: request not to schedule argument during same week as No. 17-1784, 17-1744, or companion cases 17-1575 + 17-1594). Service: 01/29/2018 by email. [493308] [John O'Quinn] [Entered: 01/29/2018 11:18 AM] (2) |
| Dec 6, 2017 | 100 | Notice from Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument ([updated from 11/14 ltr]: request not to schedule argument during February 2018 or same session as no. 17-1131, 17-1525, 17-1784, or companion cases 17-1575 + 17-1594 ). Service: 12/06/2017 by email. [480589] [John O'Quinn] [Entered: 12/06/2017 12:53 PM] (2) |
| Nov 14, 2017 | 99 | Notice from Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument ([updated from 10/17/17 ltr]: request not to schedule argument January 11 or 12, or during the same week as no. 17-1131, 17-1525, 17-1784, or companion cases 17-1575 + 17-1594). Service: 11/14/2017 by email. [475515] [John O'Quinn] [Entered: 11/14/2017 05:20 PM] (2) |
| Oct 17, 2017 | 98 | Notice from Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument (Request not to schedule argument same week as nos. 15-2021, 17-1131, or companion cases 17-1575 + 17-1594). Service: 10/17/2017 by email. [468630] [John O'Quinn] [Entered: 10/17/2017 08:07 PM] (2) |
| Oct 13, 2017 | 97 | Amended Entry of appearance for Robert D. Rhoad as of counsel for Cross-Appellant Endo Pharmaceuticals Inc.. Service: 10/13/2017 by email. [467601] [Martin Black] [Entered: 10/13/2017 11:48 AM] (3) |
| Oct 12, 2017 | 96 | REMINDER: All counsel of record are reminded of their responsibility per FCR 47.3(c)(1) and FCR 47.4(c) to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. The court notes that the contact information on the EOA for Robert D. Rhoad [17] no longer matches the information in the attorney's user account. Please file an amended EOA promptly. [467234] [MJL] [Entered: 10/12/2017 09:31 AM] (0) |
| Sep 11, 2017 | 94 | 6 paper copies of the Joint Appendix (Vols. I-II) [87] received from Appellants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [460156] [CW] [Entered: 09/11/2017 02:42 PM] (0) |
| Sep 11, 2017 | 95 | Notice from Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC regarding conflicts with oral argument (November 6, 8-9, 2017). Service: 09/11/2017 by email. [460234] [Brenda Joly] [Entered: 09/11/2017 05:36 PM] (1) |
| Sep 8, 2017 | 93 | Notice from Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument (Request that the Court not schedule any two of 15-2021, 16-2099, 17-1094, and 17-1131 during the same argument week.). Service: 09/08/2017 by email. [459875] [John O'Quinn] [Entered: 09/08/2017 04:25 PM] (2) |
| Sep 6, 2017 | 92 | Notice from Cross-Appellant Endo Pharmaceuticals Inc. regarding conflicts with oral argument (November 7-9, 2017). Service: 09/06/2017 by email. [459021] [Sharon Gagliardi] [Entered: 09/06/2017 03:06 PM] (3) |
| Sep 5, 2017 | 88 | Notice to counsel: The record of this case indicates that the Certificate of Compliance with Fed. Cir. R. 11(d) has not been filed. IF any portion of the record in the trial court is subject to a protective order, counsel should promptly file the Certificate of Compliance using the Cert of Compliance Modification of Protective Order (R11/17) event which is found in the Forms and Certificates category. Service as of this date by Clerk of Court. [458604] [MJL] [Entered: 09/05/2017 02:26 PM] (0) |
| Sep 5, 2017 | 89 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks [NOV, DEC, JAN], or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 09/12/2017. [458662] [MJL] [Entered: 09/05/2017 03:08 PM] (0) |
| Sep 5, 2017 | 90 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Appellees Actavis LLC, Actavis South Atlantic LLC, Mallinckrodt LLC, Teva Pharmaceuticals USA, Inc. and Cross-Appellant Endo Pharmaceuticals Inc.. Service: 09/05/2017 by email. [458769] [Brenda Joly] [Entered: 09/05/2017 09:06 PM] (4) |
| Sep 5, 2017 | 91 | Statement of Compliance with Fed. Cir. R. 33 for Appellants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Appellees Actavis LLC, Actavis South Atlantic LLC, Mallinckrodt LLC, Teva Pharmaceuticals USA, Inc. and Cross-Appellant Endo Pharmaceuticals Inc.. Service: 09/05/2017 by email. [458770] [Brenda Joly] [Entered: 09/05/2017 09:08 PM] (4) |
| Sep 1, 2017 | 86 | TENDERED from Appellants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Appellees Actavis LLC, Actavis South Atlantic LLC, Mallinckrodt LLC, Teva Pharmaceuticals USA, Inc. and Cross-Appellant Endo Pharmaceuticals Inc.. Title: JOINT APPENDIX. Service: 09/01/2017 by email. [458402] [Brenda Joly] [Entered: 09/01/2017 04:36 PM] (958) |
| Sep 1, 2017 | 87 | APPENDIX FILED for Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, et al. [86]. Number of Pages: 958. Service: 09/01/2017 by email. The paper copies of the appendix should be received by the court on or before 09/12/2017. [458600] [MJL] [Entered: 09/05/2017 02:24 PM] (963) |
| Aug 30, 2017 | 85 | 6 paper copies of the Reply Brief [84] received from Cross-Appellant Endo Pharmaceuticals Inc. [457717] [CW] [Entered: 08/30/2017 12:01 PM] (0) |
| Aug 25, 2017 | 83 | TENDERED from Cross-Appellant Endo Pharmaceuticals Inc.. Title: REPLY BRIEF. Service: 08/25/2017 by email. [456832] [Martin Black] [Entered: 08/25/2017 04:15 PM] (35) |
| Aug 25, 2017 | 84 | REPLY BRIEF FILED for Cross-Appellant Endo Pharmaceuticals Inc. [83]. Number of Pages: 25. Service: 08/25/2017 by email. The paper copies of the brief should be received by the court on or before 09/06/2017. Appendix is due 09/01/2017. [457273] [MJL] [Entered: 08/29/2017 10:08 AM] (35) |
| Aug 7, 2017 | 81 | **TEXT ONLY** ORDER granting motion to extend time to file cross-appellant's reply brief [80] filed by Cross-Appellant Endo Pharmaceuticals Inc. The brief is due 08/25/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [451861] [MJL] [Entered: 08/07/2017 12:30 PM] (0) |
| Aug 7, 2017 | 82 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Cross-Appellant's motion [80] selected an incorrect relief. CORRECTION: When requesting an extension for the last reply brief in a case involving a cross-appeal, the appropriate relief is "extend time to file cross-appellant's reply brief." For future motions, please ensure the correct relief is selected. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [451862] [MJL] [Entered: 08/07/2017 12:33 PM] (0) |
| Aug 4, 2017 | 79 | 6 paper copies of the Corrected Reply Brief [77] received from Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. [451584] [MJL] [Entered: 08/04/2017 02:08 PM] (0) |
| Aug 4, 2017 | 80 | MOTION of Cross-Appellant Endo Pharmaceuticals Inc. to extend the time to 08/25/2017 to file the cross-appellant's reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 08/04/2017 by email. [451692]--[Edited 08/07/2017 by clerk to correct relief and docket text] [Martin Black] [Entered: 08/04/2017 06:51 PM] (8) |
| Aug 3, 2017 | 78 | 6 paper copies of the Reply Brief [73] received from Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc., and 6 paper copies of the Notice of Joinder [74] received from Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. [451129] [MJL] [Entered: 08/03/2017 09:32 AM] (0) |
| Jul 31, 2017 | 75 | NOTICE OF REJECTION: Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC's Response and Reply Brief [70] is not in compliance with the rules of this court and is therefore rejected for filing. Corrected brief due 08/14/2017. Cross-Appellant's reply brief due 08/11/2017. Service as of this date by Clerk of Court. [450382] [MJL] [Entered: 07/31/2017 01:51 PM] (2) |
| Jul 31, 2017 | 76 | TENDERED from Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Title: CORRECTED RESPONSE BRIEF. Service: 07/31/2017 by email. [450413] [Brenda Joly] [Entered: 07/31/2017 03:06 PM] (64) |
| Jul 31, 2017 | 77 | CORRECTED REPLY BRIEF FILED for Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC [76]. Number of Pages: 52. Service: 07/31/2017 by email. The paper copies of the brief should be received by the court on or before 08/08/2017. [450586] [MJL] [Entered: 08/01/2017 10:24 AM] (64) |
| Jul 28, 2017 | 70 | TENDERED from Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Title: RESPONSE BRIEF. Service: 07/28/2017 by email. [450209]. This brief has been rejected. See Doc. No. [75]. [Brenda Joly] [Entered: 07/28/2017 05:54 PM] (0) |
| Jul 28, 2017 | 71 | TENDERED from Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Title: RESPONSE BRIEF. Service: 07/28/2017 by email. [450212] [Huiya Wu] [Entered: 07/28/2017 06:06 PM] (80) |
| Jul 28, 2017 | 72 | TENDERED from Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Title: NOTICE OF JOINDER. Service: 07/28/2017 by email. [450215] [William Burgess] [Entered: 07/28/2017 06:09 PM] (4) |
| Jul 28, 2017 | 73 | REPLY BRIEF FILED for Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [71]. Number of Pages: 71. Service: 07/28/2017 by email. The paper copies of the brief should be received by the court on or before 08/07/2017. [450351] [MJL] [Entered: 07/31/2017 12:25 PM] (80) |
| Jul 28, 2017 | 74 | Notice of Joinder for Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. [72] joining in the Reply Brief submitted by Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. ([71], [73]). Service: 07/28/2017 by email. The paper copies of the joinder should be received by the court on or before 08/07/2017. [450356] [MJL] [Entered: 07/31/2017 12:31 PM] (4) |
| Jun 19, 2017 | 69 | **TEXT ONLY** ORDER granting motion to extend time to file defendants-appellees' response brief and defendants-appellants' response and reply briefs [68] filed by Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. and Appellees Teva Pharmaceuticals USA, Inc., Actavis LLC and Actavis South Atlantic LLC. The briefs are due 07/28/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [440198] [MJL] [Entered: 06/19/2017 09:36 AM] (0) |
| Jun 16, 2017 | 68 | MOTION of Appellants Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc. and Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. to extend the time to 07/28/2017 to file the reply brief. Any response is due within 10 days of service, to extend the time to 07/28/2017 to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 06/16/2017 by email. [440152] [Leslie Schmidt] [Entered: 06/16/2017 10:31 PM] (13) |
| May 24, 2017 | 67 | 6 paper copies of the Response Brief [66] received from Appellee Mallinckrodt LLC and Cross-Appellant Endo Pharmaceuticals Inc. [434075] [KW] [Entered: 05/25/2017 10:46 AM] (0) |
| May 19, 2017 | 65 | TENDERED from Appellee Mallinckrodt LLC and Cross-Appellant Endo Pharmaceuticals Inc.. Title: RESPONSE BRIEF. Service: 05/19/2017 by email. [432987] [Sharon Gagliardi] [Entered: 05/19/2017 05:44 PM] (199) |
| May 19, 2017 | 66 | BRIEF FILED for Appellee Mallinckrodt LLC and Cross-Appellant Endo Pharmaceuticals Inc. [65]. Number of Pages: 86. Service: 05/19/2017 by email. The paper copies of the brief should be received by the court on or before 05/30/2017. Amneal Pharmaceuticals LLC et al.'s response and reply brief and Acatvis LLC et al.'s response brief are due 06/28/2017. [433148] [MJL] [Entered: 05/22/2017 12:07 PM] (199) |
| May 15, 2017 | 63 | ORDER filed. The stay of proceedings is lifted. The motion [46] is denied. Endo and Mallinckrodt's brief, not to exceed 16,500 words, is due no later than May 19, 2017. Service: 05/15/2017 by clerk. [431320] [LMS] [Entered: 05/15/2017 11:17 AM] (3) |
| May 15, 2017 | 64 | Entry of appearance for Leslie M. Schmidt as of counsel for Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 05/15/2017 by email. [431577] [Leslie Schmidt] [Entered: 05/15/2017 04:42 PM] (2) |
| May 9, 2017 | 62 | ORDER filed. The revised official caption is reflected in the order. Service: 05/09/2017 by clerk. [429961] [LMS] [Entered: 05/09/2017 01:15 PM] (2) |
| May 8, 2017 | 61 | Objection to the official caption pursuant to Rule 12 Practice Note by Appellees Actavis Elizabeth LLC, Actavis Holdco U.S., Inc. and Actavis Pharma, Inc.. Service: 05/08/2017 by email. [429741] [William Burgess] [Entered: 05/08/2017 03:36 PM] (16) |
| May 4, 2017 | 60 | Notice to counsel for Appellees Actavis Elizabeth LLC, Actavis Holdco U.S., Inc. and Actavis Pharma, Inc.: The record of this case indicates that no entry of appearance, certificate of interest, or docketing statement has been filed. Please file these documents promptly. Service as of this date by Clerk of Court. [429020] [MJL] [Entered: 05/04/2017 08:19 AM] (0) |
| May 1, 2017 | 59 | REPLY of Appellee Mallinckrodt LLC and Cross-Appellant Endo Pharmaceuticals Inc. to response filed by Appellants in 17-1094 , Doc. No [57]. Service: 05/01/2017 by email. [428331] [Sharon Gagliardi] [Entered: 05/01/2017 05:14 PM] (11) |
| Apr 26, 2017 | 58 | ORDER filed. The briefing schedule is stayed pending further order of the court. Endo and Mallinckrodt's reply is due no later than May 1, 2017. Endo and Mallinckrodt are ordered to clarify the relief sought in the reply. Service: 04/26/2017 by clerk. [427336] [LMS] [Entered: 04/26/2017 02:56 PM] (2) |
| Apr 25, 2017 | 57 | RESPONSE of Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC to the motion to waive requirements of brief or appendix [46] filed by Cross-Appellant Endo Pharmaceuticals Inc. and Appellee Mallinckrodt LLC in 17-1094. Service: 04/25/2017 by email. [427082] [Brenda Joly] [Entered: 04/25/2017 05:55 PM] (6) |
| Apr 24, 2017 | 56 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The motion [46] filed by Endo Pharmaceuticals Inc. and Mallinckrodt LLC selected an incorrect relief ("other relief"). CORRECTION: When requesting exemption from a rule regarding a brief, the appropriate relief is "waive requirements of brief or appendix." Please ensure future motions select the correct relief. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [426492] [MJL] [Entered: 04/24/2017 10:12 AM] (0) |
| Apr 21, 2017 | 46 | MOTION of Appellee Mallinckrodt LLC and Cross-Appellant Endo Pharmaceuticals Inc. TO FILE AN EXTENDED BRIEF. Any response is due within 10 days of service [Consent: partial consent]. Service: 04/21/2017 by email. [426311] [Martin Black] [Entered: 04/21/2017 03:54 PM] (10) |
| Apr 21, 2017 | 47 | Certificate of Interest for the Appellees Actavis Pharma, Inc., Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 04/21/2017 by email. [426396] [William Burgess] [Entered: 04/21/2017 09:35 PM] (4) |
| Apr 21, 2017 | 48 | Corrected Certificate of Interest for the Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 04/21/2017 by email. [426397] [William Burgess] [Entered: 04/21/2017 09:36 PM] (4) |
| Apr 21, 2017 | 49 | Docketing Statement for the Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 04/21/2017 by email. [426398] [William Burgess] [Entered: 04/21/2017 09:37 PM] (3) |
| Apr 21, 2017 | 50 | Entry of appearance for John C. O'Quinn as principal counsel for Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 04/21/2017 by email. [426399] [William Burgess] [Entered: 04/21/2017 09:40 PM] (2) |
| Apr 21, 2017 | 51 | Entry of appearance for William H. Burgess as of counsel for Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 04/21/2017 by email. [426400] [William Burgess] [Entered: 04/21/2017 09:41 PM] (2) |
| Apr 21, 2017 | 52 | Entry of appearance for James F. Hurst as of counsel for Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 04/21/2017 by email. [426401] [William Burgess] [Entered: 04/21/2017 09:42 PM] (2) |
| Apr 21, 2017 | 53 | Entry of appearance for Howard S. Suh as of counsel for Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 04/21/2017 by email. [426402] [William Burgess] [Entered: 04/21/2017 09:43 PM] (2) |
| Apr 21, 2017 | 54 | Entry of appearance for Charles A. Weiss as of counsel for Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 04/21/2017 by email. [426403] [William Burgess] [Entered: 04/21/2017 09:45 PM] (2) |
| Apr 21, 2017 | 55 | Entry of appearance for Eric H. Yecies as of counsel for Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 04/21/2017 by email. [426404] [William Burgess] [Entered: 04/21/2017 09:47 PM] (2) |
| Apr 19, 2017 | 45 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The firm information on the entries of appearance for Rodney R. Miller [41], Paul G. Williams [42], and Jeffrey J. Toney [43] does not match the information in the attorneys' user accounts. CORRECTION: Please update as needed to ensure the contact information on the entries of appearance and in the user accounts matches. [425495] [MJL] [Entered: 04/19/2017 12:11 PM] (0) |
| Apr 18, 2017 | 41 | Amended Entry of appearance for Rodney R. Miller as of counsel for Appellee Mallinckrodt LLC. Service: 04/18/2017 by email. [425308] [Rodney Miller] [Entered: 04/18/2017 06:17 PM] (2) |
| Apr 18, 2017 | 42 | Amended Entry of appearance for Paul G. Williams as of counsel for Appellee Mallinckrodt LLC. Service: 04/18/2017 by email. [425312] [Paul Williams] [Entered: 04/18/2017 06:23 PM] (2) |
| Apr 18, 2017 | 43 | Amended Entry of appearance for Jeffrey J. Toney as principal counsel for Appellee Mallinckrodt LLC. Service: 04/18/2017 by email. [425313] [Jeffrey Toney] [Entered: 04/18/2017 06:29 PM] (2) |
| Apr 18, 2017 | 44 | Amended Certificate of Interest for the Appellee Mallinckrodt LLC. Service: 04/18/2017 by email. [425314] [Jeffrey Toney] [Entered: 04/18/2017 06:32 PM] (2) |
| Apr 12, 2017 | 39 | ORDER consolidating appeals (17-1887 with 17-1094, -1240, -1444, -1455). The revised official caption is reflected in the order. Endo Pharmaceuticals Inc.'s opening brief addressing all of these appeals, and Mallinckrodt LLC's response brief addressing only issues associated with 17-1094, -1240, -1444, -1455, are due no later than 05/01/2017. Amneal Pharmaceuticals LLC et al.'s response/reply brief, addressing only issues associated with 17-1094, -1240, -1444, -1455, and Actavis LLC et al.'s response brief, addressing only issues associated with 17-1887, are due no later than 06/12/2017. Endo's reply brief is due no later than 06/26/2017. Service as of this date by Clerk of Court. [423414] [17-1094, 17-1240, 17-1444, 17-1455, 17-1887] [MJL] [Entered: 04/12/2017 11:52 AM] (2) |
| Apr 12, 2017 | 40 | Note to file: The following cases are consolidated: 17-1094 (Lead) with 17-1240, -1444, -1455, -1887 (Members). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [423608] [17-1094, 17-1240, 17-1444, 17-1455, 17-1887] [MJL] [Entered: 04/12/2017 04:33 PM] (0) |
| Mar 30, 2017 | 38 | 6 paper copies of the Opening Brief [37] received from Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [420364] [KW] [Entered: 03/30/2017 03:14 PM] (0) |
| Mar 20, 2017 | 36 | TENDERED from Appellants BARR LABORATORIES, INC. and Teva Pharmaceuticals USA, Inc.. Title: OPENING BRIEF. Service: 03/20/2017 by email. [417148] [Huiya Wu] [Entered: 03/20/2017 05:03 PM] (129) |
| Mar 20, 2017 | 37 | BRIEF FILED for Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [36]. Number of Pages: 59. Service: 03/20/2017 by email. The paper copies of the brief should be received by the court on or before 04/03/2017. [419244] [MJL] [Entered: 03/27/2017 04:18 PM] (129) |
| Mar 10, 2017 | 33 | ORDER granting motion to consolidate appeals [32] filed by Cross-Appellant Endo Pharmaceuticals Inc. and Appellee Mallinckrodt LLC. The revised official caption is reflected in the order. Because the appeals are consolidated, one set of briefs should be filed for the appeals.; Teva Pharmaceuticals USA, Inc. and Barr Laboratories, Inc.’s opening brief is due no later than 03/20/2017. Endo’s principal/response brief and Mallinckrodt’s response brief are due no later than 05/01/2017. The appellants' response/reply brief is due 06/12/2017. Endo's reply brief is due no later than 06/26/2017. Service: 03/10/2017 by clerk. [414302] [NL] [Entered: 03/10/2017 11:09 AM] (2) |
| Mar 10, 2017 | 34 | NOTE TO FILE: FOR PRIOR ENTRIES related to Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. SEE 17-1444. [414386] [JCA] [Entered: 03/10/2017 01:09 PM] (0) |
| Mar 10, 2017 | 35 | Note to file: The following cases are associated:17-1094 Lead with 17-1240, 17-1444, 17-1455 Consolidated. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [414391] [17-1094, 17-1240, 17-1444, 17-1455] [JCA] [Entered: 03/10/2017 01:13 PM] (0) |
| Mar 3, 2017 | 32 | MOTION of Appellee Mallinckrodt LLC and Cross-Appellant Endo Pharmaceuticals Inc. to consolidate appeals (2017-1094, -1240 with 2017-1444, -1455). Any response is due within 10 days of service [Consent: unopposed]. Service: 03/03/2017 by email. [412384] [Sharon Gagliardi] [Entered: 03/03/2017 01:58 PM] (11) |
| Jan 12, 2017 | 30 | MOTION of Cross-Appellant Endo Pharmaceuticals Inc. to extend the time to 04/17/2017 to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 01/12/2017 by email. [398181] [Sharon Gagliardi] [Entered: 01/12/2017 11:54 AM] (9) |
| Jan 12, 2017 | 31 | ORDER granting motion to extend time to file the cross-appellant's principal brief [30] filed by Cross-Appellant Endo Pharmaceuticals Inc.. No further extensions should be anticipated. The brief is due 04/17/2017. Service as of this date by Clerk of Court. [398328] [MJL] [Entered: 01/12/2017 03:01 PM] (2) |
| Jan 6, 2017 | 29 | Note to file: 17-1444 (COMPANION started 01/06/2017) with 17-1094, -1240. These cases shall be considered companion cases and assigned to the same merits panel for oral argument. [396685] [17-1094, 17-1444] [MJL] [Entered: 01/06/2017 11:12 AM] (0) |
| Dec 27, 2016 | 28 | 6 paper copies of the Corrected Opening Brief [27] received from Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. [394543] [JCP] [Entered: 12/27/2016 01:38 PM] (0) |
| Dec 23, 2016 | 25 | NOTICE OF REJECTION: Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC's Opening Brief [24] is not in compliance with the rules of this court and is therefore rejected for filing. Corrected brief due 01/06/2017. Cross-Appellant Endo Pharmaceuticals Inc.'s brief is due 01/31/2017. Service as of this date by Clerk of Court. [394124] [MJL] [Entered: 12/23/2016 09:22 AM] (2) |
| Dec 23, 2016 | 26 | TENDERED from Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Title: CORRECTED OPENING BRIEF. Service: 12/23/2016 by email. [394190] [Brenda Joly] [Entered: 12/23/2016 10:51 AM] (126) |
| Dec 23, 2016 | 27 | CORRECTED BRIEF FILED for Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC [26]. Number of Pages: 57. Service: 12/23/2016 by email. The paper copies of the brief should be received by the court on or before 12/28/2016. [394230] [MJL] [Entered: 12/23/2016 12:00 PM] (126) |
| Dec 22, 2016 | 24 | TENDERED from Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Title: OPENING BRIEF. Service: 12/22/2016 by email. [393990]. This brief has been rejected. See Doc. No. [25]. [Brenda Joly] [Entered: 12/22/2016 09:37 PM] (0) |
| Nov 18, 2016 | 22 | Note to file: The following cases are consolidated: 17-1094 (Lead) with 17-1240 (Cross-Appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [384634] [17-1094, 17-1240] [MJL] [Entered: 11/18/2016 02:17 PM] (0) |
| Nov 18, 2016 | 23 | Official caption revised to reflect cross-appeal. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [384646] [MJL] [Entered: 11/18/2016 02:48 PM] (0) |
| Nov 15, 2016 | 21 | Transcript Purchase Order Form for the Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC indicating that a request is made to the reporter for a transcript. Service: 11/15/2016 by clerk. [383315] [MJL] [Entered: 11/15/2016 04:25 PM] (2) |
| Nov 8, 2016 | 20 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Jonathan D. J. Loeb (entry of appearance [16]) is not a registered CM/ECF filer with the Federal Circuit. CORRECTION: Pursuant to FCR 25(a)(2), attorneys who appear before this court must register for the court's CM/ECF system. Please register promptly. [381114] [MJL] [Entered: 11/08/2016 08:32 AM] (0) |
| Nov 7, 2016 | 2 | Entry of appearance for Brenda L. Joly as of counsel for Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 11/07/2016 by email, US mail. [380856] [Brenda Joly] [Entered: 11/07/2016 01:23 PM] (2) |
| Nov 7, 2016 | 3 | Entry of appearance for Jacob M. Holdreith as principal counsel for Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 11/07/2016 by email, US mail. [380857] [Brenda Joly] [Entered: 11/07/2016 01:25 PM] (2) |
| Nov 7, 2016 | 4 | Entry of appearance for Oren D. Langer as of counsel for Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 11/07/2016 by email, US mail. [380860] [Brenda Joly] [Entered: 11/07/2016 01:27 PM] (2) |
| Nov 7, 2016 | 5 | Entry of appearance for Kelsey J. Thorkelson as of counsel for Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 11/07/2016 by email, US mail. [380862] [Brenda Joly] [Entered: 11/07/2016 01:29 PM] (2) |
| Nov 7, 2016 | 6 | Certificate of Interest for the Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 11/07/2016 by email, US mail. [380864] [Brenda Joly] [Entered: 11/07/2016 01:30 PM] (2) |
| Nov 7, 2016 | 7 | Docketing Statement for the Appellants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 11/07/2016 by email, US mail. [380867] [Brenda Joly] [Entered: 11/07/2016 01:33 PM] (3) |
| Nov 7, 2016 | 8 | Entry of appearance for Jeffrey J. Toney as principal counsel for Appellee Mallinckrodt LLC. Service: 11/07/2016 by email. [381047] [Jeffrey Toney] [Entered: 11/07/2016 05:20 PM] (2) |
| Nov 7, 2016 | 9 | Docketing Statement for the Appellee Endo Pharmaceuticals Inc.. Service: 11/07/2016 by email. [381048] [Sharon Gagliardi] [Entered: 11/07/2016 05:20 PM] (4) |
| Nov 7, 2016 | 10 | Docketing Statement for the Appellee Mallinckrodt LLC. Service: 11/07/2016 by email. [381049] [Jeffrey Toney] [Entered: 11/07/2016 05:21 PM] (4) |
| Nov 7, 2016 | 11 | Certificate of Interest for the Appellee Endo Pharmaceuticals Inc.. Service: 11/07/2016 by email. [381051] [Sharon Gagliardi] [Entered: 11/07/2016 05:22 PM] (3) |
| Nov 7, 2016 | 12 | Certificate of Interest for the Appellee Mallinckrodt LLC. Service: 11/07/2016 by email. [381052] [Jeffrey Toney] [Entered: 11/07/2016 05:22 PM] (3) |
| Nov 7, 2016 | 13 | Entry of appearance for Martin J. Black as principal counsel for Appellee Endo Pharmaceuticals Inc.. Service: 11/07/2016 by email. [381055] [Sharon Gagliardi] [Entered: 11/07/2016 05:24 PM] (2) |
| Nov 7, 2016 | 14 | Entry of appearance for Blake B. Greene as of counsel for Appellee Endo Pharmaceuticals Inc.. Service: 11/07/2016 by email. [381056] [Sharon Gagliardi] [Entered: 11/07/2016 05:26 PM] (2) |
| Nov 7, 2016 | 15 | Entry of appearance for Rodney Miller as of counsel for Appellee Mallinckrodt LLC. Service: 11/07/2016 by email. [381058] [Rodney Miller] [Entered: 11/07/2016 05:27 PM] (2) |
| Nov 7, 2016 | 16 | Entry of appearance for Jonathan D. J. Loeb as of counsel for Appellee Endo Pharmaceuticals Inc.. Service: 11/07/2016 by email. [381059] [Sharon Gagliardi] [Entered: 11/07/2016 05:28 PM] (2) |
| Nov 7, 2016 | 17 | Entry of appearance for Robert D. Rhoad as of counsel for Appellee Endo Pharmaceuticals Inc.. Service: 11/07/2016 by email. [381061] [Sharon Gagliardi] [Entered: 11/07/2016 05:30 PM] (2) |
| Nov 7, 2016 | 18 | Entry of appearance for Paul G. Williams as of counsel for Appellee Mallinckrodt LLC. Service: 11/07/2016 by email. [381062] [Paul Williams] [Entered: 11/07/2016 05:30 PM] (2) |
| Nov 7, 2016 | 19 | Entry of appearance for Sharon K. Gagliardi as of counsel for Appellee Endo Pharmaceuticals Inc.. Service: 11/07/2016 by email. [381063] [Sharon Gagliardi] [Entered: 11/07/2016 05:32 PM] (2) |
| Oct 24, 2016 | 1 | Appeal docketed. Received: 10/24/2016. [377000]Entry of Appearance due 11/07/2016. Certificate of Interest due 11/07/2016. Docketing Statement due 11/07/2016. Appellants' brief due 12/23/2016. [MJL] [Entered: 10/24/2016 11:38 AM] (55) |
